

Venous Thromboembolism: Pathophysiology & Management



Gerald A Soff MD

Chief, General Hematology Service
Sylvester Comprehensive Cancer Center,
University of Miami Health System
gas199@Miami.edu

HematologyEducationOnline


Slide 1



Jean M Connors MD


Medical Director, Anticoagulation
Management and Stewardship Services
Brigham and Women's Hospital/Dana
twitter @Connors_md

November 10, 2022



Disclosures

	Gerald A Soff MD	Jean M Connors MD
Research Support Support (Past 5 years):	<ul style="list-style-type: none">➤ Amgen➤ Janssen Scientific Affairs➤ Sobi/Dova Pharmaceuticals➤ Anthos Therapeutics	<ul style="list-style-type: none">➤ CSL Behring
Advisory Boards (In past 5 years)	<ul style="list-style-type: none">➤ Janssen Scientific Affairs➤ Sobi/Dova Pharmaceuticals➤ Luzsana (HengruiUSA) Biotechnology➤ Sanofi	<ul style="list-style-type: none">➤ Abbott➤ Alnylam➤ Anthos➤ Bristol Myers Squibb➤ Pfizer➤ Roche➤ Sanofi➤ Werfen




What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?


Not covering:

- Antiphospholipid Antibody Syndrome
- Thrombolysis In Pulmonary Embolism




What We'll Cover

- 1. Scope of the Problem**
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?




Venous Thromboembolism (1)

- Approximately 1 to 2 per 1,000 each year in the United States.
 - “Venous thromboembolism (VTE), defined as deep vein thrombosis, pulmonary embolism, or both, affects an estimated 300,000-600,000 individuals in the U.S. each year.”
 - Estimates suggest that 60,000-100,000 Americans die of VTE.
 - 10 to 30% of people will die within one month of diagnosis.
 - Incidence strongly correlates with demographics and risk factors.
-
- <https://www.cdc.gov/ncbddd/dvt/data.html>
 - Beckman et al. Am J Prev Med. 2010 Apr;38(4 Suppl):S495-501. doi: 10.1016/j.amepre.2009.12.017.




Venous Thromboembolism (2)

- Among people who have had a DVT, one third to one half will have long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb.
- One-third (about 33%) of people with DVT/PE will have a recurrence within 10 years.
- Approximately 5 to 8% of the U.S. population has one of several genetic risk factors, also known as inherited thrombophilias in which a genetic defect can be identified that increases the risk for thrombosis.
 - <https://www.cdc.gov/ncbddd/dvt/data.html>
 - Beckman et al. Am J Prev Med. 2010 Apr;38(4 Suppl):S495-501. doi: 10.1016/j.amepre.2009.12.017.




What We'll Cover

1. Scope of the Problem
- 2. Vascular Anatomy**
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?



Structure of Normal Blood Vessels




Artery

Vein


1. Arteries pump blood by peristaltic motion.
2. Veins pump blood by external compression, with series of one-way valves directing blood towards the heart.




Servier Medical Art de Servier est mis à disposition selon les termes de la licence Creative Commons Attribution 3.0 France



Intramuscular/Deep Vein Function



HematologyEducationOnline



Contraction/Relaxation of leg muscles pumps blood through deep veins.

Slide 9


November 10, 2022



Servier Medical Art de Servier est mis à disposition selon les termes de la licence Creative Commons Attribution 3.0 France




Venous Return: Superficial and Deep Veins



- Deep veins are intramuscular
- Blood flows from superficial to deep veins through perforating veins.
- Blood flow “pumped” by contraction of deep muscles.
- Flow directed by series of one-way valves.



Servier Medical Art de Servier est mis à disposition selon les termes de la licence Creative Commons Attribution 3.0 France



Prolonged Bedrest/Immobility Reduces Venous Return






Image Source: *Source: Peter Lamb*

<https://www.nursingtimes.net/clinical-archive/cardiovascular-clinical-archive/effects-of-bedrest-1-introduction-and-the-cardiovascular-system-26-11-2018/>




What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
- 3. Thrombosis: Arterial versus Venous**
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?



Venous Thrombosis



- “Red Clot”
- Abundant trapped red cells
- Tend to involve venous valves



Servier Medical Art de Servier est mis à disposition selon les termes de la licence Creative Commons Attribution 3.0 France

Arterial Thrombosis

- “White Clot”
- Few red cells
- Tend to form on atherosclerotic plaque, especially following plaque rupture.
- Risk factors ~ risks of atherosclerotic Disease.




Deep Vein Thrombosis: 5 Signs of Inflammation of Galen

1. Rubor: Erythema
2. Tumor: Edema
3. Calor: Warmth
4. Dolor: Pain
5. Functio Laesa: loss of function


- However, many patients have minimal or no symptoms.
- High index of suspicion is essential in high-risk settings.




- <https://commons.wikimedia.org/wiki/File:PCD2016.jpg>
- James Heilman, MD, CC BY-SA 4.0
<<https://creativecommons.org/licenses/by-sa/4.0/>>, via
Wikimedia Commons



Pulmonary Embolism




- Pulmonary embolism usually originates from the deep veins of the legs or pelvis.
- Venous thrombi predominantly originate in venous valve pockets and at other sites of presumed venous stasis (inset, bottom).
- If a clot propagates to the knee vein or above, or if it originates above the knee, the risk of embolism increases.
- Thromboemboli travel through the right side of the heart to reach the lungs.
 - Tapson VF. NEJM 2008;358:1037-1052.
- Sudden death is the first symptom in about one-quarter (25%) of people who have a PE.




What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
- 4. Post-Thrombotic Syndrome**
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?




Post-Thrombotic Syndrome

- Venous incompetence (Varicose veins)
- Due to destruction of venous valves associated with DVT.
- Decreased venous return increases extravascular pressure and decreased capillary blood flow, leading to tissue ischemia and venous ulcers.
- As much as half of patients will develop PTS after initial DVT.
- **Increased risk of recurrent VTE.**




<https://www.semanticscholar.org/paper/Varicose-veins%3A-evaluating-modern-treatments%2C-with-Vandy-Wakefield/6c1e53cb135bc601e10ab15879d64bfd56418ecb>



Tissue Breakdown From Post-Thrombotic Syndrome

- Reduced venous return leads to tissue edema
- Edema reduces capillary blood flow, reduced oxygen delivery
- Tissue breakdown.



Normal capillaries

Edema formation




Servier Medical Art de Servier est mis à disposition selon les termes de la licence Creative Commons Attribution 3.0 France

HematologyEducationOnline

Slide 18

November 10, 2022



Post-Thrombotic Syndrome: Chronic Venous Insufficiency/Ulcers




<https://vasocare.com/conditions/post-thrombotic-syndrome/> **HematologyEducationOnline**

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume: 15, Issue: 5, Pages: 538-556, First published: 09 May 2017, DOI: (10.1111/ddg.13242)


Slide 19

November 10, 2022




Compression therapy for prevention of post-thrombotic syndrome

- Overall, use of elastic compression stockings led to a clinically significant reduction in the incidence of PTS (risk ratio (RR) 0.62, 95% confidence interval (CI) 0.38 to 1.01; $P = 0.05$)
- Low-quality evidence suggests that elastic compression stockings may reduce the occurrence of PTS after DVT.
 - Appelen et al, Compression therapy for prevention of post-thrombotic syndrome (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
- 5. Pathophysiology of Venous Thromboembolism**
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?



Virchow's Triad: Factors Contributing to Thrombosis



Rudolf Virchow
October 13, 1821 –
September 5, 1902

➤ **Altered Blood Flow/Venous stasis**


- Immobilization
- Obesity
- Heart disease

➤ **Vessel wall damage**


- Accidental trauma
- Surgical trauma
- Prior history of DVT
- Advanced Age

➤ **Increase In Blood “Coagulability”**


- Increase in tissue factor
- Presence of activated factors
- Decrease in coagulation inhibitors




Kyrle & Eichinger. Blood, 2009



Normal Hemostatic Balance





N ENGL J MED 361;27 NEJM.ORG DECEMBER 31, 2009




Thrombophilia

- Vascular endothelial cells present anticoagulant surface.
- Disruption of endothelial surface exposes blood to Collagen and Subendothelial Matrix (procoagulants) leading to activation of coagulation.
- Deficiency of physiologic anticoagulants leads to activation of coagulation.




Physiologic Anticoagulation Processes on Endothelial Cells

Pathway	Activity	Effect
CD39-Ecto ADPase	Degrades ADP	Reduced ADP, reduced platelet activation
NO Synthase	Synthesis of Nitric Oxide	Relaxes smooth muscle and inhibits platelet activation
Cyclooxygenase 2	Synthesis of Prostacyclin (PGI₂)	Relaxes smooth muscle and inhibits platelet activation
Heparan Sulfate (Glycosaminoglycan)	Heparan binds Antithrombin	Heparan:AT complex neutralizes coagulation enzymes
Thrombomodulin & Endothelial Protein C Receptor	Thrombomodulin binds Thrombin EPCR binds protein C	Thrombin:TM complex has reduced procoagulant activity. Activates protein C which inactivates Cofactors (FVa, FVIIIa)
Tissue Factor Pathway Inhibitor	TFPI inhibits direct activation of Factor X by TF:VIIa complex	



Inherited Thrombophilias

- Approximately 5 to 8% of the U.S. population has one of several genetic risk factors, also known as inherited thrombophilia, in which a genetic defect can be identified that increases the risk for thrombosis
- Mostly Factor V:Leiden and Prothrombin G20210A
- Other hereditary thrombophilias are rare.
 - <https://www.cdc.gov/ncbddd/dvt/data.html>
 - Beckman et al. Am J Prev Med. 2010 Apr;38(4 Suppl):S495-501. doi: 10.1016/j.amepre.2009.12.017.




Established Inherited Thrombophilias: Mutations/Polymorphisms Create Coagulation Imbalance:

Increased **procoagulant** activity

- **Factor V Leiden** polymorphism
 - APC “resistance”
- **Prothrombin gene G20210A** polymorphism
 - Increased prothrombin levels



Decreased **anticoagulant** activity

- Multiple mutations lead to decreased level or altered function (quantitative vs qualitative)
- **Protein C**: inactivates FVIII and FV
- **Protein S**: cofactor for protein C
- **Antithrombin**: inactivates thrombin, Xa, and other enzymes of the coagulation system.




Factor V:Leiden: Activated Protein C Resistance

- Inactivation of Factor Va involves four sequential cleavages of the membrane-bound procofactor at Arg306, Arg506, Arg679, and Lys994.
- **Factor V:Leiden polymorphism (G1691A) (R506Q)** is associated with activated protein C resistance, prolonged/enhanced activity of Factor Va, and thrombotic tendency.




Factor V:Leiden: Activated Protein C Resistance

- Found predominantly in European populations (~7-8%), with ~1% in Indian subcontinent and Arabs.
- Heterozygotes (in isolation); ~5-fold increase risk in thrombosis.
- Homozygotes; ~ 50-fold increase in thrombotic risk.




Jorine S. Koenderman and Pieter H. Reitsma (November 9th 2011). Inherited Thrombophilia: Past, Present, and Future Research, Thrombophilia, Andrea Luigi Tranquilli, IntechOpen, DOI: 10.5772/26050. Available from: <https://www.intechopen.com/books/thrombophilia/inherited-thrombophilia-past-present-and-future-research>




Prothrombin Gene Mutation: (Prothrombin G20210A)

- G → A point mutation at position 20210 in the 3' untranslated region of the prothrombin (factor II) gene.
- Genetic polymorphism associated with increased mRNA half-life and Prothrombin levels.
- ~ 3-fold increased risk of thrombosis.
 - Poort et al Blood. 1996;88(10):3698.
- ~1.7-3% % of population in Europe and European ancestry.
 - Rosendaal, F. R. et al. Thromb. Haemost. 79: 706-708, 1998.
- Arose approximately 24,000 years ago.
 - Zivelin et al. Blood 107: 4666-4668, 2006




Prothrombin G20210A




The prothrombin G20210A mutation is a single G-to-A point mutation at position 20210 in the 3' untranslated region of the prothrombin (factor II) gene. The mutation does not affect the protein-coding region (exons) of the gene.

Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19.




Homocysteine Metabolism

- Elevated Homocysteine levels associated with increased incidence of both arterial and venous thrombosis.
- **Cystathionine Beta Synthase(CBS) deficiency.**
(Homocysteinuria)
 - Autosomal recessive, Severe congenital
 - Connective tissue, muscles, central nervous system (CNS), and cardiovascular system.
- **Methylene Tetrahydrofolate Reductase (MTHFR)**
 - Autosomal recessive. Milder form
 - Homocysteine (Hcy) levels only increased with concomitant deficiency of folic acid and other B-vitamins.
 - Hcy levels decreased with folic acid or combination vitamin therapy.
 - den Heijer et al. Arterioscler Thromb Vasc Biol. 18:356, 1998.




Azzini et al. Int. J. Mol. Sci. 2020, 21(4), 1421; <https://doi.org/10.3390/ijms21041421>



MTHFR/Homocysteine Association with VTE?

- It remains unresolved if there is an association of MTHFR homozygosity or mild to moderate homocysteine elevation is associated with increased risk of VTE.
- Most contemporary guidance documents do not recommend testing for MTHFR or serum homocysteine levels in evaluation for hypercoagulability.
 - Bezemer, Arch Int Med 2007
 - Naess, BJH 2008




Coagulation Abnormalities Causing Inherited Thrombophilia and Associated RR of VTE.

Causes	Prevalence (%)	Relative risk of first venous thrombosis
Antithrombin deficiency	0.02	5–10
Protein C deficiency	0.2	4–6.5
Protein S deficiency	0.03–0.13	1–10
Factor V Leiden	3.0–7.0	3–5
Prothrombin G20210A	0.7–4.0	2–3


- **These are dominant traits.**
- **50% levels or heterozygous state is associated with thrombotic tendency.**

Middeldorp S. *Hematology Am Soc Hematol Educ Program* (2016) 2016 (1): 1–9 <https://doi.org/10.1182/asheducation-2016.1.1>




“Non-O Blood Type Is an Important Genetic Risk Factor for VTE”

- Non-O blood group, Odds Ratio of VTE: 2.1 – 2.5
 - Dentali et al. *Semin Thromb Hemost* 2012;38:535–548.
 - Franchini & Makris. *Blood Transfus.* 2013 Apr; 11(2): 164–165.
- ABO is associated with von Willebrand Factor (VWF) and coagulation Factor VIII plasma levels.
- While ABO Blood type is associated with thrombotic risk, it is not routinely considered in hypercoagulable workup, or impact on VTE management.



What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
- 6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias**
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?



Acquired Thrombophilias


Disease-Based

- Antiphospholipid Syndrome *
- Malignancy *
- Myeloproliferative neoplasms
- Nephrotic syndrome
- Paroxysmal nocturnal hemoglobinuria


Situational

- Pregnancy *
- Obesity
- Exogenous estrogen
- Prior VTE
- Major Surgery
- Trauma
- Immobilization
- Venous catheters


* To be discussed in future presentations.



Annual Incidence of Venous Thromboembolism By Age and Sex




Heit J A Hematology 2007;2007:127-135



Multiplicative Effect of Risk Factors For Thrombosis


	Odds Ratio (95% CI)
Normal genotype without oral contraceptives	1 (Reference)
Normal genotype with oral contraceptives	4.6 (2.6–8.0)
Factor II:A20210 without oral contraceptives	2.7 (0.6–12.7)
Factor V:A1691 without oral contraceptives	2.4 (0.4–15.1)
Factor II:A20210 with oral contraceptives	16.3 (3.4–79.1)
Factor V:A1691 with oral contraceptives	20.0 (4.2–94.3)

- The Multiplicative Effect or synergy of risk factors holds true with acquired and hereditary factors.
- i.e. Oral contraceptives, pregnancy, surgery, medical illnesses, etc.
 - Martinelli et al. Arteriosclerosis, Thrombosis, and Vascular Biology Volume 19, Issue 3, March 1999; Pages 700-703. <https://doi.org/10.1161/01.ATV.19.3.700>



What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
- 7. Thrombophilia: Prevalence, Evaluation, and Impact**
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?



Clinical Characteristics Suggestive of Inherited Thrombophilia in Patients with Venous Thromboembolism (VTE)

Table 1. Clinical Characteristics Suggestive of Inherited Thrombophilia in Patients with Venous Thromboembolism (VTE).

Thrombosis at a young age (<50 yr), especially in association with weak provoking factors (minor surgery, combination oral contraceptives, or immobility) or unprovoked VTE

Strong family history of VTE (first-degree family members affected at a young age)


Recurrent VTE events, especially at a young age*

VTE in unusual sites such as splanchnic or cerebral veins†

* The antiphospholipid syndrome must also be considered, but it is not inherited.

† Patients with splanchnic-vein VTE should be assessed for myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria.

Connors JM. N Engl J Med 2017;377:1177-1187



Molecular/Biochemical Risk Factors Of Thromboembolic Disease

➤ **Common**

- G1691A mutation in the factor V gene (**factor V Leiden**)
- G20210A mutation in the prothrombin (**factor II**) gene
- **Antiphospholipid Antibody Syndrome**


➤ **Rare**

- **Antithrombin III deficiency**
- **Protein C deficiency**
- **Protein S deficiency**

➤ **Very rare**


- Dysfibrinogenemia/Alterations in fibrinolysis.

- Except for DNA analysis, do not work-up during acute event, pregnancy, oral contraceptives, acute medical/surgical illness.




Thrombophilia Testing and Venous Thrombosis


- “After full-intensity anticoagulant therapy has been started, the next step in the management of VTE is to determine the duration of anticoagulation. **The role that thrombophilia status plays in this decision-making process is limited...**
- For patients with VTE who are found to have an inherited thrombophilia, it is the provoked or unprovoked nature of the VTE, not the thrombophilia, that drives decisions about the duration of anticoagulant therapy.”
 - Connors. NEJM 2017; 377:1177-1187 DOI: 10.1056/NEJMra1700365
- **Identification of Antiphospholipid Antibody Syndrome may impact management.**



Thrombophilias Are Not Associated with a Higher Risk of Recurrent VTE *




Christiansen et al. JAMA 2005;293(19):2353-61




Kearon C et al. Blood 2008;112:4432-6

*** Antiphospholipid Antibody Syndrome is associated with higher rate of recurrent VTE**




Antiphospholipid Antibody Syndrome

To be discussed in future lecture!




What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
- 8. Treatment of Venous Thromboembolism: Historical Perspective**
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?




Heparin: “An Indirect Anticoagulant” Dependent of Antithrombin III


Unfractionated Heparin



Factor Xa



Thrombin



Antithrombin




Factor Xa




Thrombin



LMWH




Factor Xa




Thrombin



Vitamin K Pathway/Warfarin



- Vitamin K Antagonists reduce synthesis of coagulation factors (II, VII, IX, X, C, S), but does not “inhibit” function.



Management of Venous Thromboembolic Disease

ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISM A CONTROLLED TRIAL


D. W. BARRITT
M.D. Lond., M.R.C.P.

Lancet 1(7138): 1309-1312, 1960.

S. C. JORDAN
M.B. Brist.

*From the Departments of Medicine and Cardiology,
United Bristol Hospitals*

- Randomized, controlled study of anticoagulation versus no treatment.
- Med/Surg. patients with PE (based on history, physical exam, pulmonary infarction on CXR, and right heart strain on EKG).
- Treatment:
 - Heparin 10,000 units q 6 hours, for 6 doses without laboratory control.
 - Acenocoumarol (VKA) adjusted for Prothrombin Time
- *Established the paradigm of initial use of heparin (low molecular weight heparin) followed by vitamin K antagonist.*



Management of Venous Thromboembolic Disease: Heparin/Warfarin

➤ Initial:


- Unfractionated Heparin
 - Titrate to aPTT or anti-Actor Xa level
- Low Molecular Weight Heparin: Enoxaparin
 - 1 mg/kg twice daily
 - 1.5 mg/kg once daily
- Continue 5-7 days, until warfarin is therapeutic.


➤ Maintenance

➤ Warfarin


- Target INR of 2.0-3.0
 - (INR is derived from the Prothrombin Time)
- May have transient hypercoagulable state when first started, due to suppression of Protein C prior to full anticoagulant effect.

Had not changed much in 50 years!






Elizabeth Renner, Geoffrey D. Barnes, Journal of the American College of Cardiology, Volume 76, Issue 18, 2020, Pages 2142-2154, ISSN 0735-1097, <https://doi.org/10.1016/j.jacc.2020.07.070>.




What We'll Cover

1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
- 9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)**
10. Reversal of Anticoagulant Effect of DOAC
11. How Long To Treat With Anticoagulation After VTE?




Direct Oral Anticoagulant (DOAC)

- Small molecules targeting the active site of a specific enzyme (Xa or IIa).
- Not dependent on a cofactor.
- Readily absorbed orally
- “Direct” anticoagulants in that they do not require the presence of a cofactor, such as antithrombin III, for function.
 - Soff. Arterioscler Thromb Vasc Biol 2012, 32:569-574. doi: 10.1161/ATVBAHA.111.242834




Perzborn E et al. Arterioscler Thromb Vasc Biol. 2010;30:376-381




Steps In Coagulation

Coagulation Pathway


Inhibitory Drugs



Adapted from Soff, Arteriosclerosis, Thrombosis, and Vascular Biology 2012, 32:569-574.




➤ *Mostly based on cancer literature, use of DOACs in patients with underlying GI or GU luminal pathology is associated with increased bleeding. Warfarin or maintenance LMWH may be preferable in those settings.*




What We'll Cover


1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
- 10. Reversal of Anticoagulant Effect of DOAC**
11. How Long To Treat With Anticoagulation After VTE?





Idarucizumab for Dabigatran Reversal




- Humanized anti-dabigatran FAb fragment.
- Two separate boluses of 2.5 g given no more than 15 min apart.
 - Pollack CV *et al*, N Engl J Med 2017.




Anti-Factor Xa Activity and Percent Change from Baseline in Patients Receiving Rivaroxaban and Apixaban



Connolly SJ et al. N Engl J Med 2016;375:1131-1141.




Recommend all patients on a DOAC wear medical alert bracelet!




Andexanet Versus Prothrombin Complex Concentrates

- In vitro studies indicate that Andexanet is more effective than 4-Factor prothrombin complex concentrate (KCentra ®) in reversing DOAC anticoagulation.
 - Lu et al. Res Pract Thromb Haemost. 2020;00:1–13.
- Only advantage of PCC is cost.



What We'll Cover


1. Scope of the Problem
2. Vascular Anatomy
3. Thrombosis: Arterial versus Venous
4. Post-Thrombotic Syndrome
5. Pathophysiology of Venous Thromboembolism
6. Pathophysiology of Venous Thromboembolism: Acquired Thrombophilias
7. Thrombophilia: Prevalence, Evaluation, and Impact
8. Treatment of Venous Thromboembolism: Historical Perspective
9. Treatment of Venous Thromboembolism: Direct Oral Anticoagulant (DOAC)
10. Reversal of Anticoagulant Effect of DOAC
11. **How Long To Treat With Anticoagulation After VTE?**




Risks for Recurrent VTE After Initial Unprovoked VTE:

- Post-Thrombotic Syndrome
- Obesity, BMI ≥ 30
- Older Age, Different studies, ≥ 50 Yr., ≥ 65 Yr.,
- Male

- Not routinely used:
 - Residual vein thrombosis. (Probably a surrogate for Post-Thrombotic Syndrome.)
 - Positive D-Dimer, one month after discontinuation of warfarin.



VTE Recurrence Rate as a Function of Provoking Factors




Unprovoked

Non-Surgical Provoked

Post-Operative Provoked

- Post-operative thrombosis have very low recurrence rate. (Removal of risk)
- Non-surgical triggers (Reduced risk)
- Unprovoked: No reduction in risk factors, presumably hereditary.
- Baglin et al. The Lancet. 362: 523-526, 2003.




Duration of Anticoagulation

Provoked


- 3 months may be sufficient if risk factor has resolved.
- 1% risk per year of recurrence, not changed by 3 vs 6 months

Idiopathic

- Recurrence rate highest in first 2 years, but persists indefinitely.
 - 10% per year in 1st 2 years
 - 40% at 5 years




Prandoni *Haematologica* 2007




Duration of Anticoagulation

- Treatment duration is more difficult to determine in patients with VTE that don't fall neatly into the provoked or unprovoked category or occur in patients with continually present/non-modifiable VTE risk factors.
- 2019 ESC PE Guidelines:
“Terminology such as ‘provoked’ vs. ‘unprovoked’ PE/ VTE is no longer supported by the Guidelines, as it is potentially misleading and not helpful for decision-making regarding the duration of anticoagulation.”


(European Heart Journal 2019)



Recurrence of VTE According to Site of First Event and Sex





Kyrle, JTH, 2017




Extended Prophylaxis: Apixaban

- Compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy.



Agnelli G et al. NEJM 2013;368:699-708.




Rivaroxaban versus Aspirin For Extended Thrombosis Secondary Prophylaxis

- Patients with VTE, completed 6-12 months of anticoagulation.
- Randomized to:
- Rivaroxaban 20 mg daily
- Rivaroxaban 10 mg daily
- ASA 100 mg daily

	Riva 20 mg	Riva 10 mg	ASA
Symptomatic recurrent VTE	1.5% *	1.2% *	4.4%
Major Bleeding	0.5%	0.4%	0.3%
CRNMB	2.7%	2.0%	1.8%

* P<0.001

Weitz et al, NEJM 2017;376:1211-22.



EINSTEIN-CHOICE


EINSTEIN Choice

3,364 participants

60% provoked

40% unprovoked

Patients in equipoise for need to continue anticoagulation.




Kaplan–Meier Cumulative Event Rates

Weitz NEJM 2017

HematologyEducationOnline



Slide 73

November 10, 2022




Meta-analysis: which is more important for your patient?


Preventing recurrent VTE?




Preventing major and CRNM Bleeding?



line




Vasanthamohan
JTH 2018



Extended Duration Anticoagulation

- **After full intensity anticoagulation for unprovoked VTE consider change to reduced dose apixaban or rivaroxaban**
- **For provoked VTE with persistent risks and for patients in equipoise, switch to reduced dose apixaban or rivaroxaban**
 - Unclear provoking factors
 - Post thrombotic syndrome or significant persistent residual vein thrombosis
 - Obesity, heart failure, immobile
 - No contraindication to DOAC use
- **Patients who should not be on reduced dose**
 - Antiphospholipid syndrome
 - Mechanical heart valves (should not be on a DOAC)
 - Atrial fibrillation
 - Cancer? Trials of reduced dose apixaban in progress



"That's all Folks!"

